The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

Last year
R&D

Deb­o­rah Birx en­ters new phase as biotech CEO; Ve­rastem chief an­nounces his re­tire­ment

Last year
Peer Review

Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Last year
Startups
Deals

Up­dat­ed: In Fri­day IPO dou­ble­head­er, Apogee and Sagimet help crack open a stuck win­dow on Wall Street

Last year
Financing
Startups

CMS pro­pos­es cov­er­age for pre-ex­po­sure pro­phy­lax­is reg­i­mens to pre­vent HIV

Last year
Pharma
FDA+

GSK's newest so­cial me­dia cam­paign of­fers 're­al­i­ty check' for lu­pus pa­tients

Last year
Pharma
Marketing

FDA ap­proves first over-the-counter birth con­trol pill, ex­pect­ed to hit shelves in 2024

Last year
Pharma
FDA+

Pfiz­er, BioN­Tech de­ny Ar­bu­tus and Genevant’s Covid vac­cine patent in­fringe­ment claims

Last year
Pharma
Law

FDA drafts new guid­ance on man­u­fac­tur­ing cell and gene ther­a­pies, post­mar­ket tri­al non­com­pli­ance

Last year
Cell/Gene Tx
FDA+

Cham­ber of Com­merce looks to halt drug price ne­go­ti­a­tions be­fore they be­gin

Last year
Law

Pfiz­er clin­i­cal tri­al reg­istry aims to re­cruit one mil­lion peo­ple for re­search

Last year
R&D
Pharma

FDA backs new $82M mR­NA man­u­fac­tur­ing cen­ter at MIT

Last year
Pharma
Cell/Gene Tx

Man­u­fac­tur­ing roundup: Cipla re­calls al­buterol dos­es over de­fect in the con­tain­er; Cell and gene ther­a­py man­u­fac­tur­er ...

Last year
Manufacturing

ICER re­vis­es sick­le cell gene ther­a­py re­port, preps to dig in­to what CMS ne­go­ti­a­tions might look like

Last year
Pharma

Bi­cy­cle rides to $200M pay­day, while lung dis­ease biotech rais­es $80M

Last year
News Briefing

Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

Last year
Startups
Deals

First Wave’s mid-stage tri­al for yeast-de­rived cys­tic fi­bro­sis drug ‘like­ly’ failed, com­pa­ny says

Last year
R&D

Causaly, an AI start­up help­ing with pre­clin­i­cal dis­cov­ery, nabs $60M from VCs and for­mer J&J chief Alex Gorsky

Last year
Financing
Startups

Mer­ck KGaA, Mil­li­pore­Sig­ma make in­vest­ments in the US and Chi­na man­u­fac­tur­ing

Last year
China
Manufacturing

UK VC firm launch­es strate­gic re­view, pon­ders shut­down

Last year
Financing

Lil­ly’s Sig­ilon buy­out came more than a year af­ter the di­a­betes cell ther­a­py part­ner first broached the idea

Last year
Pharma

Af­ter eject­ing out of Bris­tol My­ers R&D, Ru­pert Vessey lands at the top sci­ence post at a buzzy Flag­ship

Last year
People
Bioregnum

From hours to min­utes? Genen­tech says Ocre­vus sub­cu­ta­neous for­mu­la­tion works just as well as IV

Last year
R&D

Bio­Gen­er­a­tion Ven­tures clos­es $167M fund to hatch Eu­ro­pean star­tups with back­ing from Eli Lil­ly, No­vo, BMS

Last year
Financing
Startups
First page Previous page 312313314315316317318 Next page Last page
A service from the Financial Times